RESEARCH TRIANGLE PARK, N.C., Jan. 3 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Neil Frazer, M.B., Ch.B., FRCA, FFPM has joined the company as Chief Medical Officer.
Prior to joining Chimerix, Dr. Frazer served as the Chief Medical Officer and Chief Operating Officer of Erimos Pharmaceuticals (previously Biocure Medical) where he was responsible for the design of clinical drug development programs to meet U.S. and global commercial, regulatory and scientific objectives. Prior to his tenure at Erimos, Dr. Frazer served as the Vice President, Clinical Research at Shire Pharmaceuticals where he was responsible for clinical drug development of key programs that included Adderall XR, Equetro and Fosrenol. Dr. Frazer has also held research and development positions at Pharmalink FHI, Medicab, Inc., TabSafe Medical Services, Inc., ClinTrials Research Inc. and Glaxo Wellcome, Inc. Dr. Frazer obtained his B.Sc. and medical degree from the University of Edinburgh Medical School.
"Dr. Frazer's years of research and development experience will be invaluable as we continue to advance our pipeline of orally available and topical antiviral agents through the clinical development process," said Dr. George Painter, Chimerix' President and CEO. "In addition to Dr. Frazer, we have also made a number of key hires in our research and development department, while maintaining our virtual research and development operating model to maintain maximum flexibility and cash efficiency."
With the addition of the new staff, Chimerix currently has 16 full-time employees. To accommodate the new employees, Chimerix has moved its headquarters to 2505 Meridian Parkway, Durham, NC 27713.
About Chimerix
Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events.
CONTACT: media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007, sneath@pnlifesciences.com, for Chimerix, Inc.; or
Athanasios (Thanos) Maroglou of Chimerix, Inc., +1-919-806-1074,
tmaroglou@chimerix-inc.com
